Dr. Febbo on the Impact of Oncotype DX Genetic Prostate Score

Phil Febbo, MD
Published: Friday, May 05, 2017



Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

As the interest in active surveillance continues to grow, the question becomes choosing patients who are the best candidates, explains Febbo. GPS will help choose who is the right patient to go on active surveillance.

If a patient goes on active surveillance they receive a score to determine their individualized risk of having aggressive disease.
 
SELECTED
LANGUAGE


Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

As the interest in active surveillance continues to grow, the question becomes choosing patients who are the best candidates, explains Febbo. GPS will help choose who is the right patient to go on active surveillance.

If a patient goes on active surveillance they receive a score to determine their individualized risk of having aggressive disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x